Prostate cancer therapy using an engineered respiratory syncytial virus
OwnerWeidong Zhang, Lixian Jiang +1inventors
InventorsWeidong Zhang, Lixian Jiang, Calvin Cao
Life of this patent
Estimating the term…
Abstract
The present invention is within the field of oncolytic virotherapy. Oncolytic virotherapy is a strategy using viruses, naturally occurring or genetically modified, to selectively target and destroy tumor cells while leaving surrounding non-malignant cells unharmed Here, an engineered respiratory syncytial virus (RSV), with the NS1 gene deleted (NS1 gene-deficient RSV, ΔNS1 RSV), kills prostate cancer cells, but does not affect normal human cells.
Claims3
A method to treat prostate cancer in a patient in need thereof by delivering directly to the cancer an oncolytic engineered respiratory syncytial virus (RSV) with the NS1 gene deleted, wherein the RSV infects and causes oncolysis to thereby treat the patient.
Dependencies are inferred from the claim text.